Evidence map›Paper›PMID 34326328›Full record

ArticleNature communications2021

BRCA2 binding through a cryptic repeated motif to HSF2BP oligomers does not impact meiotic recombination.

Rania Ghouil, Simona Miron, Lieke Koornneef, Jasper Veerman, Maarten W Paul, Marie-Hélène Le Du, Esther Sleddens-Linkels, Sari E van Rossum-Fikkert, Yvette van Loon, Natalia Felipe-Medina and 8 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Rania Ghouil *Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Uni Paris-Sud, Uni Paris-Saclay, Gif-sur-Yvette, France.
Simona Miron *Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Uni Paris-Sud, Uni Paris-Saclay, Gif-sur-Yvette, France.
Lieke Koornneef *Department of Developmental Biology, Oncode Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.ORCID 0000-0001-9742-9580
Jasper VeermanDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.ORCID 0000-0002-3107-979X
Maarten W PaulDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.ORCID 0000-0002-7990-6010
Marie-Hélène Le DuInstitute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Uni Paris-Sud, Uni Paris-Saclay, Gif-sur-Yvette, France.
Esther Sleddens-LinkelsDepartment of Developmental Biology, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.
Sari E van Rossum-FikkertDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.
Yvette van LoonDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.
Natalia Felipe-MedinaMolecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.
Alberto M PendasMolecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.ORCID 0000-0001-9264-3721
Alex MaasDepartment of Cell Biology, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.
Jeroen EssersDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.
Pierre LegrandSynchrotron SOLEIL, L'Orme des Merisiers, Gif-sur-Yvette, France.ORCID 0000-0003-2431-2255
Willy M BaarendsDepartment of Developmental Biology, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands.ORCID 0000-0002-9179-850X
Roland KanaarDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands. r.kanaar@erasmusmc.nl.
Sophie Zinn-JustinInstitute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Uni Paris-Sud, Uni Paris-Saclay, Gif-sur-Yvette, France. Sophie.ZINN@cea.fr.
Alex N ZelenskyDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands. a.zelensky@erasmusmc.nl.ORCID 0000-0002-2664-271X
Erasmus MC · NLCentre National de la Recherche Scientifique · FRUniversidad de Salamanca · ESSynchrotron soleil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA2 and its interactors are required for meiotic homologous recombination (HR) and fertility. Loss of HSF2BP, a BRCA2 interactor, disrupts HR during spermatogenesis. We test the model postulating that HSF2BP localizes BRCA2 to meiotic HR sites, by solving the crystal structure of the BRCA2 fragment in complex with dimeric armadillo domain (ARM) of HSF2BP and disrupting this interaction in a mouse model. This reveals a repeated 23 amino acid motif in BRCA2, each binding the same conserved surface of one ARM domain. In the complex, two BRCA2 fragments hold together two ARM dimers, through a large interface responsible for the nanomolar affinity - the strongest interaction involving BRCA2 measured so far. Deleting exon 12, encoding the first repeat, from mBrca2 disrupts BRCA2 binding to HSF2BP, but does not phenocopy HSF2BP loss. Thus, results herein suggest that the high-affinity oligomerization-inducing BRCA2-HSF2BP interaction is not required for RAD51 and DMC1 recombinase localization in meiotic HR.

Indexed as

AnimalsBRCA2 ProteinCell Cycle ProteinsCells, CulturedCrystallography, X-RayFemaleHomologous RecombinationHumansMagnetic Resonance SpectroscopyMaleMeiosisMiceModels, AnimalProtein Interaction Domains and MotifsSequence DeletionSpermatogenesisBRCA2 ProteinBRCA2 protein, humanCell Cycle ProteinsHSF2BP protein, human

Identifiers

PMID34326328
PMCPMC8322138
OpenAlexW3183395603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.